Sailong Pharmaceutical Group Co.,Ltd. - Laporan Laba Rugi (TTM)

Sailong Pharmaceutical Group Co.,Ltd.
CN ˙ SZSE
CN¥ 14.15 ↓ -0.19 (-1.32%)
2025-09-08
BAHAGING PRESYO
Laporan Laba Rugi (TTM)

Laporan Laba Rugi Sailong Pharmaceutical Group Co.,Ltd. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2022
01-01
2022
03-31
2022
06-30
2022
09-30
2023
01-01
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 205 121 157 161 179 247 241 249 254 264 281 290 297 311 301 310 304 264 248 243
Change (%) -41.22 29.81 2.95 11.15 37.83 -2.46 3.49 2.04 3.81 6.52 2.91 2.46 4.68 -3.20 3.07 -1.91 -13.30 -5.84 -2.00
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 54 46 63 65 76 87 89 99 105 128 140 151 162 171 176 181 180 177 162 188
Change (%) -14.22 35.83 3.25 17.10 14.00 2.76 10.69 6.22 22.03 9.58 7.53 7.29 5.86 2.94 2.78 -0.62 -1.74 -8.26 15.96
% of Revenue 26.29 38.37 40.16 40.27 42.43 35.09 36.97 39.54 41.16 48.39 49.78 52.02 54.47 55.08 58.58 58.41 59.18 67.07 65.35 77.32
Gross Operating Profit 151 74 94 96 103 160 152 151 150 136 141 139 135 140 125 129 124 87 86 55
Change (%) -50.85 26.05 2.75 7.14 55.39 -5.29 -0.73 -0.70 -8.93 3.64 -1.66 -2.78 3.27 -10.73 3.47 -3.71 -30.06 -0.91 -35.86
% of Revenue 73.71 61.63 59.84 59.73 57.57 64.91 63.03 60.46 58.84 51.61 50.22 47.98 45.53 44.92 41.42 41.59 40.82 32.93 34.65 22.68
SG&A 143 122 135 131 126 160 156 155 154 150 149 141 135 95 83 91 92 82 82 63
Change (%) -14.23 10.45 -3.40 -3.13 26.64 -2.88 -0.40 -0.49 -2.47 -0.64 -5.38 -4.47 -29.35 -12.83 9.24 1.34 -11.34 0.10 -22.60
% of Revenue 69.50 101.41 86.29 80.96 70.56 64.83 64.55 62.12 60.59 56.92 53.09 48.81 45.51 30.71 27.66 29.32 30.29 30.97 32.93 26.01
R&D 26 26 26 25 24 21 21 24 24 24 27 27 28 28 26 24 24 25 25 23
Change (%) 0.52 1.56 -4.42 -1.96 -12.36 -4.15 17.42 0.28 -2.75 13.34 1.50 2.06 -0.23 -7.02 -7.07 2.22 0.81 2.92 -7.26
% of Revenue 12.44 21.27 16.64 15.45 13.63 8.67 8.52 9.66 9.50 8.90 9.47 9.34 9.30 8.86 8.51 7.68 8.00 9.30 10.16 9.62
OpEx 225 197 228 225 232 273 270 283 289 307 320 323 329 297 288 299 299 286 273 280
Change (%) -12.11 15.75 -1.41 2.96 17.77 -1.12 4.64 2.12 6.28 4.45 0.82 1.80 -9.58 -3.02 3.57 -0.01 -4.09 -4.75 2.59
% of Revenue 109.35 163.51 145.81 139.64 129.34 110.52 112.04 113.28 113.37 116.07 113.81 111.50 110.78 95.69 95.87 96.33 98.19 108.62 109.88 115.03
Operating Income -19 -77 -72 -64 -53 -26 -29 -33 -34 -42 -39 -33 -32 13 12 11 5 -23 -25 -37
Change (%) 299.09 -6.38 -10.93 -17.72 -50.58 11.61 14.16 2.72 24.77 -8.40 -14.34 -3.93 -141.83 -7.12 -8.48 -51.75 -513.92 7.98 49.03
% of Revenue -9.35 -63.51 -45.81 -39.64 -29.34 -10.52 -12.04 -13.28 -13.37 -16.07 -13.81 -11.50 -10.78 4.31 4.13 3.67 1.81 -8.62 -9.88 -15.03
Interest Expense -5 -6 -6 -7 -7 -7 -8 -6 -7 -8 -7 -8 -9 -7 -7 -6 -7 -7 -7 -8
Change (%) 26.48 2.26 14.55 -0.39 -1.19 16.19 -17.57 3.87 23.20 -14.20 22.32 0.44 -18.95 5.12 -11.29 4.81 -0.38 4.03 8.54
% of Revenue -2.20 -4.74 -3.74 -4.16 -3.72 -2.67 -3.18 -2.53 -2.58 -3.06 -2.46 -2.93 -2.87 -2.22 -2.41 -2.08 -2.22 -2.55 -2.82 -3.12
Net Income -13 -67 -58 -45 -34 -23 -24 -32 -33 -37 -35 -35 -35 10 8 8 2 -33 -36 -50
Change (%) 417.82 -14.32 -22.58 -24.09 -31.05 3.35 31.43 5.49 11.56 -5.14 -0.05 -1.95 -127.49 -16.50 4.40 -81.75 -2,285.66 8.03 38.91
% of Revenue -6.32 -55.70 -36.77 -27.65 -18.88 -9.45 -10.01 -12.71 -13.14 -14.12 -12.58 -12.22 -11.69 3.07 2.65 2.68 0.50 -12.58 -14.43 -20.45

Source: Capital IQ

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista